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Sex and fat—Can one factor handle both?
It has become increasingly evident that, in addition to determining female sex development, estradiol plays additional
important roles in both males and females, not the least of which is regulation of energy homeostasis. A new study by
D’Eon et al. (2005) now further highlights this role.
P R E V I E W SThe concept of estradiol as the female
sex hormone and testosterone as the
male sex hormone has undergone a con-
siderable makeover in recent years. This
is based on the realization that both hor-
mones coexist in males and females and
can have numerous roles, many of which
have nothing to do with sex or reproduc-
tion. Thus, it has recently been shown, in
studies with genetically modified mice
and in patients with natural mutations in
the human aromatase and ERa genes
(Oz et al., 2000; Carani et al., 1997; Smith
et al., 1994), that estrogen plays just as
important a role in the maintenance of
healthy bones in males as it does in fe-
males. Sex hormones are also involved
in the cardiovascular system and in brain
function. Additionally, it has become in-
creasingly apparent that sex hormones
perform key roles in energy homeostasis.
It is now quite well documented that sys-
temic loss of estrogen at menopause
is associated with increased adiposity,
which can be prevented by estrogen re-
placement. Studies in mice bearing inac-
tivating mutations in either aromatase,
the enzyme responsible for estrogen bio-
synthesis (ArKO), or in the ERa estrogen
receptor (ERKO) have shown that these
mice develop a full-blownmetabolic syn-
drome characterized by increased vis-
ceral and gonadal fat, hyperleptinemia,
hyperinsulinemia, and decreased phys-
ical activity (Heine et al., 2000; Jones
et al., 2000; Misso et al., 2003). Moreover
both of these models exhibit a sexually
dimorphic hepatic steatosis that, inter-
estingly, is male specific (Hewitt et al.,
2004). In the case of the ArKO mice, it
was shown that the increase in visceral
adiposity was primarily due to an in-
crease in the expression of lipoprotein
lipase (LPL) rather than increased de
novo synthesis of fatty acids. Estradiol
replacement produced a dramatic de-
crease in adiposity, a decrease in the
expression of LPL and leptin, and an
increase in adipose tissue fatty-acid
b-oxidation. The male-specific hepatic
steatosis was shown to be accompanied
by an increase in the expression of fatty-346acid synthase (FAS) and acetylCoA car-
boxylase-1 (ACC-1), a phenotype that
could be reversed by estradiol replace-
ment. A muscle phenotype of the ArKO
mice was also suggested by decreased
physical activity, a decrease in lean
bodymass and rate of glucose oxidation,
and an increase inmuscle triglycerides. A
complicating factor in these studies is the
fact that both the ArKO and the ERKO
models show elevated circulating andro-
gens. This issue was obviated in a recent
publication by D’Eon et al. in the Journal
of Biological Chemistry (D’Eon et al.,
2005). The authors employed ovariecto-
mized mice as their study model. Since
it is a well-established dogma that the
adrenals of rodents do not secrete an-
drogenic steroids, it is reasonable to con-
clude, although this was not in fact deter-
mined, that the circulating testosterone
level in these animals is extremely low.
The authors also employed a pair-feed-
ing paradigm in order to avoid the issue
that ovariectomy induces hyperphagia
in rodents, which is itself ameliorated by
estradiol replacement. Thus they were
able to define how estrogen protects
against increased adiposity in this model
independently of differences in energy in-
take.
Following 60 days of replacement with
estradiol in the form of implants, it was
found that estrogen treatment decreased
total adiposity as well as adipocyte size
in the visceral fat depots but not in sub-
cutaneous fat. Circulating leptin and
resistin were both decreased, as was cir-
culating adiponectin. In the adipose tis-
sue, estrogen replacement resulted in a
decrease in the expression of factors
and enzymes, such as LPL, LXRa,
SREBP-1c, FAS and ACC-1, involved
in triglyceride synthesis. Employing iso-
lated adipocytes, it was shown that the
estradiol-treated mice had higher iso-
proterenol-stimulated lipolysis as deter-
mined by glycerol release. Western
analysis of blots for perilipin and HSL ex-
pression revealed that this was due to
higher perilipin expression in cells from
the estradiol-treated mice, as there wasno significant difference in HSL protein
expression.
The muscle tissue of these animals
was also investigated in this study. In
muscle from the ovariectomized mice,
estrogen treatment resulted in decreased
expression of SREBP-1c and its down-
stream targets, FAS andACC-1. Estrogen
treatment also resulted in an increased
expression of PPARg and its down-
stream targets such as UCP2 and 3,
ACOX, and PDK4. Thus, as in the fat, es-
trogen administration resulted in de-
creased fat synthesis and increased en-
ergy utilization in muscle. Since AMP
kinase is implicated in lipid homeostasis
in muscle, the effect of estrogen treat-
ment on AMP kinase activation was de-
termined employing Western blots of
phosphorylated AMP kinase (T172).
AMP kinase, by regulating intracellular
signals, acts as a fuel gauge regulating
fat oxidation, fatty-acid synthesis, and
glucose uptake. Activation of AMP kinase
results in inactivation of ACC, thus pre-
venting the synthesis of malonyl CoA,
a metabolite necessary for triglyceride
synthesis. This in turn increases carnitine
palmitoyl transferase-1 activity and al-
lows for long-chain fatty-acid transport
into the mitochondria for oxidation (Fig-
ure 1; reviewed in Kahn et al., 2005). It
was found that muscle from the estro-
gen-treated mice had higher levels of
phosphorylated AMP kinase when nor-
malized for total kinase protein. In a fur-
ther attempt to determine if there was
a direct action of estradiol on the muscle
cells, C2C12 myocytes in culture were
employed and estrogen at different con-
centrations was added to the culture me-
dium. Estradiol caused increased phos-
phorylation of AMP kinase within 5 min
in a dose-dependent fashion, and this
phosphorylation was fully inhibited by
ICI 182780, a pure estrogen receptor an-
tagonist. However, a feature of this ex-
periment that is difficult to reconcile is
that there appeared to be little change
in the phosphorylation of AMP kinase at
estrogen levels of 10 and 100 nmol.
This effect was only seen at higher levels,CELL METABOLISM : DECEMBER 2005
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Figure 1. Proposed role of estrogen in the activation of the AMP kinase pathway regulating fatty-acid
b-oxidationnamely 1 mmol and 10 mmol estradiol.
Since the estrogen receptor is fully satu-
rated at concentrations of 1 nmol, it is
hard to imagine that this was an ERa-
or ERb-mediated event, although this
was suggested by the blockade by the
estrogen receptor inhibitor. One possible
speculation is that there could have been
an extremely rapid metabolism of the es-
tradiol by these cultured CTC12 myo-
cytes, although this had not been tested.
This study is a useful addition to the
previously published work employing
genetically modified mouse models of
estrogen insufficiency. Based on their
observations, the authors suggest that
estradiol reduces adiposity by the en-
hancement of pathways that promote
fatty-acid oxidation in muscle, inhibition
of fat storage in adipose tissue, liver,
and muscle, and enhanced rates of adi-
pocyte lipolysis. In addition, they suggest
that estradiol, through upregulation of
PPARg expression, acts in muscle to al-
ter fuel partitioning and oxidative capac-
ity and thus enhance muscle oxidation.
Whereas these results can be explained
by classical genomic actions of estradiol,
the in vitro studies suggest that estradiolCELL METABOLISM : DECEMBER 2005could also act in a rapid nongenomic
manner to phosphorylate, and thus acti-
vate, AMP kinase in muscle. Although
this reported action of estradiol is intrigu-
ing, the fact that high concentrations of
estradiol were required in order to
achieve this effect leaves the door open
to other interpretations.
This is an important issue that should
be clarified since it is now becoming ap-
parent from these, and other studies, that
not only estradiol but also testosterone
play important roles in the regulation of
energy homeostasis. Humans with natu-
ral mutations in aromatase develop a
metabolic syndrome (Maffei et al., 2004),
but hypogonadal men also have a strong
tendency toward obesity. Moreover,
polycystic ovarian syndrome in women,
which is characterized by hyperandroge-
nicity, is frequently alsomarked by insulin
resistance and type II diabetes. These
results are confusing and seemingly con-
flicting, and the issuewill only be resolved
by careful analysis of animalmodels such
as the one described in this report as well
as the use of transgenic mouse models
employing tissue-specific knockouts and
knockins.Evan R. Simpson
and Kerry J. McInnes
Prince Henry’s Institute of Medical
Research and Departments
of Biochemistry and Anatomy
Monash University
Melbourne
Victoria 3168
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